Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

R. Rais, KM. Lemberg, L. Tenora, ML. Arwood, A. Pal, J. Alt, Y. Wu, J. Lam, JMH. Aguilar, L. Zhao, DE. Peters, C. Tallon, R. Pandey, AG. Thomas, RP. Dash, T. Seiwert, P. Majer, RD. Leone, JD. Powell, BS. Slusher

. 2022 ; 8 (46) : eabq5925. [pub] 20221116

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22032634

6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist that suppresses cancer cell metabolism but concurrently enhances the metabolic fitness of tumor CD8+ T cells. DON showed promising efficacy in clinical trials; however, its development was halted by dose-limiting gastrointestinal (GI) toxicities. Given its clinical potential, we designed DON peptide prodrugs and found DRP-104 [isopropyl(S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)-propanamido)-6-diazo-5-oxo-hexanoate] that was preferentially bioactivated to DON in tumor while bioinactivated to an inert metabolite in GI tissues. In drug distribution studies, DRP-104 delivered a prodigious 11-fold greater exposure of DON to tumor versus GI tissues. DRP-104 affected multiple metabolic pathways in tumor, including decreased glutamine flux into the TCA cycle. In efficacy studies, both DRP-104 and DON caused complete tumor regression; however, DRP-104 had a markedly improved tolerability profile. DRP-104's effect was CD8+ T cell dependent and resulted in robust immunologic memory. DRP-104 represents a first-in-class prodrug with differential metabolism in target versus toxicity tissue. DRP-104 is now in clinical trials under the FDA Fast Track designation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032634
003      
CZ-PrNML
005      
20230131151841.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1126/sciadv.abq5925 $2 doi
035    __
$a (PubMed)36383674
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rais, Rana $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000340592453
245    10
$a Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug / $c R. Rais, KM. Lemberg, L. Tenora, ML. Arwood, A. Pal, J. Alt, Y. Wu, J. Lam, JMH. Aguilar, L. Zhao, DE. Peters, C. Tallon, R. Pandey, AG. Thomas, RP. Dash, T. Seiwert, P. Majer, RD. Leone, JD. Powell, BS. Slusher
520    9_
$a 6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist that suppresses cancer cell metabolism but concurrently enhances the metabolic fitness of tumor CD8+ T cells. DON showed promising efficacy in clinical trials; however, its development was halted by dose-limiting gastrointestinal (GI) toxicities. Given its clinical potential, we designed DON peptide prodrugs and found DRP-104 [isopropyl(S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)-propanamido)-6-diazo-5-oxo-hexanoate] that was preferentially bioactivated to DON in tumor while bioinactivated to an inert metabolite in GI tissues. In drug distribution studies, DRP-104 delivered a prodigious 11-fold greater exposure of DON to tumor versus GI tissues. DRP-104 affected multiple metabolic pathways in tumor, including decreased glutamine flux into the TCA cycle. In efficacy studies, both DRP-104 and DON caused complete tumor regression; however, DRP-104 had a markedly improved tolerability profile. DRP-104's effect was CD8+ T cell dependent and resulted in robust immunologic memory. DRP-104 represents a first-in-class prodrug with differential metabolism in target versus toxicity tissue. DRP-104 is now in clinical trials under the FDA Fast Track designation.
650    _2
$a lidé $7 D006801
650    12
$a prekurzory léčiv $x farmakologie $x terapeutické užití $7 D011355
650    _2
$a diazooxonorleucin $x farmakologie $x terapeutické užití $7 D003980
650    _2
$a glutamin $x metabolismus $7 D005973
650    _2
$a CD8-pozitivní T-lymfocyty $x metabolismus $7 D018414
650    12
$a nádory $x farmakoterapie $7 D009369
650    _2
$a inhibitory enzymů $x terapeutické užití $7 D004791
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lemberg, Kathryn M $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000315119322
700    1_
$a Tenora, Lukáš $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 16000, Czech Republic $1 https://orcid.org/0000000269823545
700    1_
$a Arwood, Matthew L $u The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA $1 https://orcid.org/0000000347379786
700    1_
$a Pal, Arindom $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000330052728
700    1_
$a Alt, Jesse $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000154407891
700    1_
$a Wu, Ying $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000262884636
700    1_
$a Lam, Jenny $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000279153530
700    1_
$a Aguilar, Joanna Marie H $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000204991927
700    1_
$a Zhao, Liang $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA $1 https://orcid.org/0000000221266778
700    1_
$a Peters, Diane E $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000341856203
700    1_
$a Tallon, Carolyn $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/000000034888547X
700    1_
$a Pandey, Rajeev $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/000000021368323X
700    1_
$a Thomas, Ajit G $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000159225050
700    1_
$a Dash, Ranjeet P $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
700    1_
$a Seiwert, Tanguy $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000179198272
700    1_
$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague 16000, Czech Republic $1 https://orcid.org/0000000218046934
700    1_
$a Leone, Robert D $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA $1 https://orcid.org/0000000229838531
700    1_
$a Powell, Jonathan D $u Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA $1 https://orcid.org/0000000208502852
700    1_
$a Slusher, Barbara S $u Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA $u Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $u Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA $1 https://orcid.org/0000000198144157
773    0_
$w MED00188818 $t Science advances $x 2375-2548 $g Roč. 8, č. 46 (2022), s. eabq5925
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36383674 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151836 $b ABA008
999    __
$a ok $b bmc $g 1891410 $s 1183969
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 8 $c 46 $d eabq5925 $e 20221116 $i 2375-2548 $m Science advances $n Sci Adv $x MED00188818
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options